Zurich, SWITZERLAND – 16. May 2018 — Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, the inclusion of alfapump®...Read More
Zurich, SWITZERLAND – 19. March 2018 — Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled study in Quality of Life Research (https://link.springer.com/journal/11136). The study demonstrated that patients with refractory ascites treated with alfapump® system have...Read More
Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of “Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis”, the results of the first 56 patients in the alfapump® multicentre Post-Marketing Surveillance Registry (PMSR) in AP&T...Read More
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.